US6645969B1
(en)
|
1991-05-10 |
2003-11-11 |
Aventis Pharmaceuticals Inc. |
Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
|
US5480883A
(en)
*
|
1991-05-10 |
1996-01-02 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
|
USRE37650E1
(en)
|
1991-05-10 |
2002-04-09 |
Aventis Pharmacetical Products, Inc. |
Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
|
AU658646B2
(en)
*
|
1991-05-10 |
1995-04-27 |
Rhone-Poulenc Rorer International (Holdings) Inc. |
Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
|
US5714493A
(en)
*
|
1991-05-10 |
1998-02-03 |
Rhone-Poulenc Rorer Pharmaceuticals, Inc. |
Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
|
US5721237A
(en)
*
|
1991-05-10 |
1998-02-24 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
|
US5710158A
(en)
*
|
1991-05-10 |
1998-01-20 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
|
GB9121943D0
(en)
*
|
1991-10-16 |
1991-11-27 |
Sandoz Ltd |
Organic compounds,processes for their production and their use
|
AU661533B2
(en)
*
|
1992-01-20 |
1995-07-27 |
Astrazeneca Ab |
Quinazoline derivatives
|
US5763441A
(en)
*
|
1992-11-13 |
1998-06-09 |
Sugen, Inc. |
Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
|
US5792771A
(en)
*
|
1992-11-13 |
1998-08-11 |
Sugen, Inc. |
Quinazoline compounds and compositions thereof for the treatment of disease
|
US5981569A
(en)
*
|
1992-11-13 |
1999-11-09 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
|
US5712395A
(en)
*
|
1992-11-13 |
1998-01-27 |
Yissum Research Development Corp. |
Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
|
GB9323290D0
(en)
*
|
1992-12-10 |
1994-01-05 |
Zeneca Ltd |
Quinazoline derivatives
|
US5409886A
(en)
*
|
1993-02-18 |
1995-04-25 |
Mitsui Toatsu Chemicals, Incorporated |
3-pyrroline-2-one derivatives and herbicidal compositions containing same
|
US5451603A
(en)
*
|
1993-03-11 |
1995-09-19 |
Zymogenetics, Inc. |
3,4-diarylchromans for treatment of dermatitis
|
GB9314893D0
(en)
*
|
1993-07-19 |
1993-09-01 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9325217D0
(en)
*
|
1993-12-09 |
1994-02-09 |
Zeneca Ltd |
Pyrimidine derivatives
|
US5416098A
(en)
*
|
1993-12-30 |
1995-05-16 |
Zymogenetics, Inc. |
Method for treating dermatitis and related conditions
|
US5700823A
(en)
*
|
1994-01-07 |
1997-12-23 |
Sugen, Inc. |
Treatment of platelet derived growth factor related disorders such as cancers
|
IL112248A0
(en)
*
|
1994-01-25 |
1995-03-30 |
Warner Lambert Co |
Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
|
IL112249A
(en)
|
1994-01-25 |
2001-11-25 |
Warner Lambert Co |
Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
|
EP0746554A1
(en)
*
|
1994-02-23 |
1996-12-11 |
Pfizer Inc. |
4-heterocyclyl-substituted quinazoline derivatives, processes for their preparation and their use as anti-cancer agents
|
AU2096895A
(en)
*
|
1994-03-07 |
1995-09-25 |
Sugen, Incorporated |
Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
|
US5578609A
(en)
*
|
1994-03-25 |
1996-11-26 |
The Dupont Merck Pharmaceutical Company |
2-carbocyclic and 2-heterocyclic quinoline-4-carboxylic acids and salts thereof useful as immunosuppressive agents
|
US5523408A
(en)
*
|
1994-03-25 |
1996-06-04 |
The Dupont Merck Pharmaceutical Company |
2-carbocyclic and 2-heterocyclic quinoline-4-carboxylic acids and salts thereof useful as immunosuppressive agents
|
ES2109796T3
(es)
*
|
1994-05-03 |
1998-01-16 |
Ciba Geigy Ag |
Derivados de pirrolopirimidilo con efecto antiproliferante.
|
GB9514160D0
(en)
*
|
1994-07-25 |
1995-09-13 |
Zeneca Ltd |
Aromatic compounds
|
GB9417532D0
(en)
*
|
1994-08-31 |
1994-10-19 |
Zeneca Ltd |
Aromatic compounds
|
US5476851A
(en)
*
|
1994-09-08 |
1995-12-19 |
Rhone-Poulenc Rorer Pharmaceuticals, Inc. |
Pyrazolo[3,4-g]quinoxaline compounds which inhibit PDGF receptor protein tyrosine kinase
|
GB9420557D0
(en)
*
|
1994-10-12 |
1994-11-30 |
Zeneca Ltd |
Aromatic compounds
|
US5804396A
(en)
*
|
1994-10-12 |
1998-09-08 |
Sugen, Inc. |
Assay for agents active in proliferative disorders
|
AU700964B2
(en)
*
|
1994-11-10 |
1999-01-14 |
Cor Therapeutics, Inc. |
Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases
|
TW321649B
(el)
*
|
1994-11-12 |
1997-12-01 |
Zeneca Ltd |
|
IL115256A0
(en)
*
|
1994-11-14 |
1995-12-31 |
Warner Lambert Co |
6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
|
GB9424233D0
(en)
*
|
1994-11-30 |
1995-01-18 |
Zeneca Ltd |
Quinazoline derivatives
|
US6562854B2
(en)
|
1994-12-14 |
2003-05-13 |
Axys Pharmaceuticals, Inc. |
Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders
|
CN1101386C
(zh)
*
|
1995-03-14 |
2003-02-12 |
诺瓦蒂斯有限公司 |
三取代的苯基衍生物
|
WO1996030347A1
(en)
|
1995-03-30 |
1996-10-03 |
Pfizer Inc. |
Quinazoline derivatives
|
DE69609602T2
(de)
*
|
1995-04-03 |
2001-04-12 |
Novartis Ag |
Pyrazolderivate und verfahren zu deren herstellung
|
US5721277A
(en)
*
|
1995-04-21 |
1998-02-24 |
Sugen, Inc. |
Compounds and methods for inhibiting hyper-proliferative cell growth
|
DE69613367T2
(de)
*
|
1995-04-27 |
2002-04-18 |
Astrazeneca Ab |
Chinazolin derivate
|
GB9508535D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivative
|
GB9508538D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9508565D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quiazoline derivative
|
GB9508537D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
US5620981A
(en)
*
|
1995-05-03 |
1997-04-15 |
Warner-Lambert Company |
Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
|
IL117923A
(en)
*
|
1995-05-03 |
2000-06-01 |
Warner Lambert Co |
Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
|
US6331555B1
(en)
|
1995-06-01 |
2001-12-18 |
University Of California |
Treatment of platelet derived growth factor related disorders such as cancers
|
US5747498A
(en)
|
1996-05-28 |
1998-05-05 |
Pfizer Inc. |
Alkynyl and azido-substituted 4-anilinoquinazolines
|
US5763470A
(en)
*
|
1995-06-07 |
1998-06-09 |
Sugen Inc. |
Benzopyran compounds and methods for their use
|
US5710173A
(en)
*
|
1995-06-07 |
1998-01-20 |
Sugen, Inc. |
Thienyl compounds for inhibition of cell proliferative disorders
|
US6147106A
(en)
|
1997-08-20 |
2000-11-14 |
Sugen, Inc. |
Indolinone combinatorial libraries and related products and methods for the treatment of disease
|
US6316635B1
(en)
|
1995-06-07 |
2001-11-13 |
Sugen, Inc. |
2-indolinone derivatives as modulators of protein kinase activity
|
EP0832073B1
(en)
*
|
1995-06-07 |
2002-01-16 |
Sugen, Inc. |
Quinazolines and pharmaceutical compositions
|
US5880141A
(en)
*
|
1995-06-07 |
1999-03-09 |
Sugen, Inc. |
Benzylidene-Z-indoline compounds for the treatment of disease
|
AU6112896A
(en)
*
|
1995-06-07 |
1996-12-30 |
Sugen, Inc. |
Tyrphostin-like compounds for the treatment of cell prolifer ative disorders or cell differentiation disorders
|
US5773459A
(en)
*
|
1995-06-07 |
1998-06-30 |
Sugen, Inc. |
Urea- and thiourea-type compounds
|
US5650415A
(en)
*
|
1995-06-07 |
1997-07-22 |
Sugen, Inc. |
Quinoline compounds
|
TW502026B
(en)
|
1995-06-20 |
2002-09-11 |
Zeneca Ltd |
Aromatic compounds useful as antagonists of e-type prostaglandins, processes for the preparation thereof, pharmaceutical compositions comprising the compounds, and intermediates
|
TW434240B
(en)
*
|
1995-06-20 |
2001-05-16 |
Zeneca Ltd |
Aromatic compounds, preparation thereof and pharmaceutical composition comprising same
|
DK0836605T3
(da)
*
|
1995-07-06 |
2002-05-13 |
Novartis Ag |
Pyrrolopyrimidiner og fremgangsmåder til deres fremstilling
|
EP0752421B1
(en)
|
1995-07-07 |
2005-10-12 |
AstraZeneca AB |
Ortho-substituted aromatic compounds, containing three (het)aryl moieties, their preparation and their use as prostaglandin E2-(PGE2)-antagonists
|
AU710128B2
(en)
|
1995-07-26 |
1999-09-16 |
Astrazeneca Ab |
Chimeric receptors and methods for identifying compounds active at metabotropic glutamate receptors and the use of such compounds in the treatment of neurological disorders and diseases
|
WO1997010813A1
(en)
|
1995-09-18 |
1997-03-27 |
Ligand Pharmaceuticals Incorporated |
Ppar gamma antagonists for treating obesity
|
US7119174B2
(en)
|
1995-12-18 |
2006-10-10 |
Sugen, Inc. |
Diagnosis and treatment of AUR1 and/or AUR2 related disorders
|
US6716575B2
(en)
|
1995-12-18 |
2004-04-06 |
Sugen, Inc. |
Diagnosis and treatment of AUR1 and/or AUR2 related disorders
|
GB9624482D0
(en)
|
1995-12-18 |
1997-01-15 |
Zeneca Phaema S A |
Chemical compounds
|
SK285141B6
(sk)
*
|
1996-02-13 |
2006-07-07 |
Astrazeneca Uk Limited |
Použitie chinazolínového derivátu, chinazolínový derivát, spôsob jeho prípravy a farmaceutická kompozícia, ktorá ho obsahuje
|
GB9603095D0
(en)
*
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9603097D0
(en)
*
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline compounds
|
EP0885198B1
(en)
|
1996-03-05 |
2001-12-19 |
AstraZeneca AB |
4-anilinoquinazoline derivatives
|
US6818660B2
(en)
|
1996-04-09 |
2004-11-16 |
Nps Pharmaceuticals, Inc. |
Calcilytic compounds
|
US6022894A
(en)
|
1996-04-09 |
2000-02-08 |
Nps Pharmaceuticals, Inc. |
Method of using calcilytic compounds
|
EP0892789B2
(en)
|
1996-04-12 |
2009-11-18 |
Warner-Lambert Company LLC |
Irreversible inhibitors of tyrosine kinases
|
GB9607729D0
(en)
*
|
1996-04-13 |
1996-06-19 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9707800D0
(en)
|
1996-05-06 |
1997-06-04 |
Zeneca Ltd |
Chemical compounds
|
US6297198B1
(en)
|
1996-05-14 |
2001-10-02 |
Syngenta Participations Ag |
Isoxazole derivatives and their use as herbicides
|
US6696448B2
(en)
|
1996-06-05 |
2004-02-24 |
Sugen, Inc. |
3-(piperazinylbenzylidenyl)-2-indolinone compounds and derivatives as protein tyrosine kinase inhibitors
|
US6060478A
(en)
*
|
1996-07-24 |
2000-05-09 |
Dupont Pharmaceuticals |
Azolo triazines and pyrimidines
|
US6313124B1
(en)
|
1997-07-23 |
2001-11-06 |
Dupont Pharmaceuticals Company |
Tetrazine bicyclic compounds
|
US6124289A
(en)
*
|
1996-07-24 |
2000-09-26 |
Dupont Pharmaceuticals Co. |
Azolo triazines and pyrimidines
|
US6191131B1
(en)
|
1997-07-23 |
2001-02-20 |
Dupont Pharmaceuticals Company |
Azolo triazines and pyrimidines
|
US7094782B1
(en)
|
1996-07-24 |
2006-08-22 |
Bristol-Myers Squibb Company |
Azolo triazines and pyrimidines
|
JP3243733B2
(ja)
*
|
1996-08-07 |
2002-01-07 |
雪印乳業株式会社 |
新規イソキノリン誘導体
|
US6682921B1
(en)
|
1996-08-21 |
2004-01-27 |
New York University |
Crystals of the tyrosine kinase domain of non-insulin receptor tyrosine kinases
|
CA2262421C
(en)
|
1996-08-23 |
2007-10-02 |
Novartis Ag |
Substituted pyrrolopyrimidines and processes for their preparation
|
US6004967A
(en)
*
|
1996-09-13 |
1999-12-21 |
Sugen, Inc. |
Psoriasis treatment with quinazoline compounds
|
GB9718972D0
(en)
|
1996-09-25 |
1997-11-12 |
Zeneca Ltd |
Chemical compounds
|
ATE300521T1
(de)
|
1996-09-25 |
2005-08-15 |
Astrazeneca Ab |
Chinolin-derivate die den effekt von wachstumsfaktoren wie vegf vezögern
|
AU719392B2
(en)
*
|
1996-10-01 |
2000-05-11 |
Kyowa Hakko Kirin Co., Ltd. |
Nitrogen-containing heterocyclic compounds
|
WO1998014450A1
(en)
|
1996-10-02 |
1998-04-09 |
Novartis Ag |
Pyrimidine derivatives and processes for the preparation thereof
|
US5827898A
(en)
*
|
1996-10-07 |
1998-10-27 |
Shaman Pharmaceuticals, Inc. |
Use of bisphenolic compounds to treat type II diabetes
|
EP0837063A1
(en)
*
|
1996-10-17 |
1998-04-22 |
Pfizer Inc. |
4-Aminoquinazoline derivatives
|
US6225318B1
(en)
|
1996-10-17 |
2001-05-01 |
Pfizer Inc |
4-aminoquinazolone derivatives
|
TW483881B
(en)
|
1996-12-03 |
2002-04-21 |
Nps Pharma Inc |
Calcilytic compounds
|
US7202261B2
(en)
|
1996-12-03 |
2007-04-10 |
Nps Pharmaceuticals, Inc. |
Calcilytic compounds
|
AU749750B2
(en)
*
|
1997-02-05 |
2002-07-04 |
Warner-Lambert Company |
Pyrido {2,3-d} pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
|
US6498163B1
(en)
|
1997-02-05 |
2002-12-24 |
Warner-Lambert Company |
Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
|
EP1806348A3
(en)
*
|
1997-02-05 |
2008-01-02 |
Warner-Lambert Company LLC |
Pyrido [2, 3 -d] pyrimidines and 4-amino-primidines as inhibitors of cellular proliferation
|
US6818440B2
(en)
|
1997-04-28 |
2004-11-16 |
Sugen, Inc. |
Diagnosis and treatment of alk-7 related disorders
|
AR012634A1
(es)
|
1997-05-02 |
2000-11-08 |
Sugen Inc |
Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
|
US6316429B1
(en)
|
1997-05-07 |
2001-11-13 |
Sugen, Inc. |
Bicyclic protein kinase inhibitors
|
US6486185B1
(en)
|
1997-05-07 |
2002-11-26 |
Sugen, Inc. |
3-heteroarylidene-2-indolinone protein kinase inhibitors
|
US6316479B1
(en)
|
1997-05-19 |
2001-11-13 |
Sugen, Inc. |
Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
|
US6228641B1
(en)
|
1997-05-20 |
2001-05-08 |
Sugen, Inc. |
Diagnosis and treatment of PTP04 related disorders
|
US6159978A
(en)
*
|
1997-05-28 |
2000-12-12 |
Aventis Pharmaceuticals Product, Inc. |
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
|
US6180632B1
(en)
*
|
1997-05-28 |
2001-01-30 |
Aventis Pharmaceuticals Products Inc. |
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
|
US6245760B1
(en)
*
|
1997-05-28 |
2001-06-12 |
Aventis Pharmaceuticals Products, Inc |
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
|
ATE286886T1
(de)
*
|
1997-05-28 |
2005-01-15 |
Aventis Pharma Inc |
Chinolin- und chinoxalin-verbindungen die den von blutplättchen abstammmenden wachstumsfaktor und/oder pdgf- und p56lck-tyrosin-kinase hemmen
|
US6987113B2
(en)
|
1997-06-11 |
2006-01-17 |
Sugen, Inc. |
Tyrosine kinase inhibitors
|
US6342593B1
(en)
|
1997-06-11 |
2002-01-29 |
Sugen, Inc. |
Diagnosis and treatment of ALP related disorders
|
US7115710B2
(en)
|
1997-06-11 |
2006-10-03 |
Sugen, Inc. |
Diagnosis and treatment of PTP related disorders
|
US6388063B1
(en)
|
1997-06-18 |
2002-05-14 |
Sugen, Inc. |
Diagnosis and treatment of SAD related disorders
|
US6376670B1
(en)
|
1997-06-19 |
2002-04-23 |
Sepracor Inc. |
Quinoline-indole antimicrobial agents, uses and compositions related thereto
|
US6103905A
(en)
*
|
1997-06-19 |
2000-08-15 |
Sepracor, Inc. |
Quinoline-indole antimicrobial agents, uses and compositions related thereto
|
US6207679B1
(en)
|
1997-06-19 |
2001-03-27 |
Sepracor, Inc. |
Antimicrobial agents uses and compositions related thereto
|
AU757059B2
(en)
|
1997-06-19 |
2003-01-30 |
Sepracor, Inc. |
Quinoline-indole antimicrobial agents, uses and compositions related thereto
|
US6313158B1
(en)
|
1997-06-20 |
2001-11-06 |
Sugen, Inc. |
Bioavailability of 3-heteroarylidenyl-2-indolinones active as protein tyrosine kinase inhibitors
|
US6051593A
(en)
|
1997-06-20 |
2000-04-18 |
Sugen, Inc. |
3-(cycloalkanoheteroarylidenyl)-2- indolinone protein tyrosine kinase inhibitors
|
US6114371A
(en)
*
|
1997-06-20 |
2000-09-05 |
Sugen, Inc. |
3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors
|
US6130238A
(en)
*
|
1997-06-20 |
2000-10-10 |
Sugen, Inc. |
3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors
|
US6235769B1
(en)
|
1997-07-03 |
2001-05-22 |
Sugen, Inc. |
Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase
|
WO1999005161A1
(en)
|
1997-07-25 |
1999-02-04 |
Ligand Pharmaceuticals Incorporated |
HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA (PPARη) GENE REGULATORY SEQUENCES AND USES THEREFOR
|
WO1999007701A1
(en)
|
1997-08-05 |
1999-02-18 |
Sugen, Inc. |
Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
|
ES2235353T3
(es)
*
|
1997-08-20 |
2005-07-01 |
Warner-Lambert Company Llc |
Naftridonas para inhibir la proteina tirasina quinasa y proliferacion celular mediada por la quinasa del ciclo celular.
|
ES2289791T3
(es)
|
1997-08-22 |
2008-02-01 |
Astrazeneca Ab |
Derivados de oxindolilquinazolina como inhibidores de la angiogenesis.
|
PT1017384E
(pt)
|
1997-09-26 |
2005-03-31 |
Zentaris Gmbh |
Compostos com base no azabenzimidazole para modulacao da funcao de uma cinase de proteina serina/treonina
|
US6133305A
(en)
|
1997-09-26 |
2000-10-17 |
Sugen, Inc. |
3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
|
UA71555C2
(en)
*
|
1997-10-06 |
2004-12-15 |
Zentaris Gmbh |
Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
|
JP2001518502A
(ja)
|
1997-10-06 |
2001-10-16 |
ビーエーエスエフ アクチェンゲゼルシャフト |
チロシンキナーゼ活性を阻害するためのインデノ[1,2−c]ピラゾール誘導体
|
ATE249217T1
(de)
*
|
1997-10-06 |
2003-09-15 |
Abbott Gmbh & Co Kg |
Indeno(1,2-c)-,naphtho(1,2-c)-und benzo(6, 7)cyclohepta(1,2-c)pyrazolderivate
|
US6225346B1
(en)
|
1997-10-24 |
2001-05-01 |
Sugen, Inc. |
Tyrphostin like compounds
|
EP1215208B1
(en)
*
|
1997-10-27 |
2006-07-12 |
Agouron Pharmaceuticals, Inc. |
4-Aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases
|
HUP0004512A3
(en)
*
|
1997-10-27 |
2003-01-28 |
Agouron Pharmaceuticals Inc La |
4-aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases
|
US6150379A
(en)
*
|
1997-11-26 |
2000-11-21 |
Axys Pharmaceuticals, Inc. |
Compounds and compositions as anticoagulants
|
US5932580A
(en)
*
|
1997-12-01 |
1999-08-03 |
Yissum Research And Development Company Of The Hebrew University Of Jerusalem |
PDGF receptor kinase inhibitory compounds their preparation and compositions
|
DK0924209T3
(da)
*
|
1997-12-19 |
2003-08-25 |
Lilly Co Eli |
Hypoglykæmiske imidazolinforbindelser
|
AU2237899A
(en)
|
1998-01-21 |
1999-08-09 |
Sugen, Inc. |
Human orthologues of wart
|
US6531502B1
(en)
|
1998-01-21 |
2003-03-11 |
Sugen, Inc. |
3-Methylidenyl-2-indolinone modulators of protein kinase
|
US6756367B2
(en)
*
|
1998-02-03 |
2004-06-29 |
Novartis Ag |
Benzo-oxadiazoles, -thiadiazoles and -1,4-diazines, pharmaceutical compositions containing them and a process for preparing them
|
AU3363599A
(en)
*
|
1998-03-26 |
1999-10-18 |
Max-Planck Institut Fur Biochemie |
Heterocyclic families of compounds for the modulation of tyrosine protein kinase
|
EP1067123B1
(en)
|
1998-03-31 |
2011-01-19 |
Kyowa Hakko Kirin Co., Ltd. |
Nitrogenous heterocyclic compounds
|
US6514981B1
(en)
|
1998-04-02 |
2003-02-04 |
Sugen, Inc. |
Methods of modulating tyrosine protein kinase function with indolinone compounds
|
CN1305470A
(zh)
|
1998-04-10 |
2001-07-25 |
日本烟草产业株式会社 |
脒化合物
|
EP1073723B1
(en)
|
1998-04-14 |
2005-08-17 |
Sugen, Inc. |
Ste20-related protein kinases
|
US6569868B2
(en)
|
1998-04-16 |
2003-05-27 |
Sugen, Inc. |
2-indolinone derivatives as modulators of protein kinase activity
|
US6706721B1
(en)
|
1998-04-29 |
2004-03-16 |
Osi Pharmaceuticals, Inc. |
N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
|
PL344248A1
(en)
|
1998-05-26 |
2001-10-22 |
Warner Lambert Co |
Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
|
EP1801112A1
(en)
*
|
1998-05-26 |
2007-06-27 |
Warner-Lambert Company LLC |
Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
|
AU759226B2
(en)
|
1998-05-29 |
2003-04-10 |
Sugen, Inc. |
Pyrrole substituted 2-indolinone protein kinase inhibitors
|
ID27600A
(id)
|
1998-06-02 |
2001-04-12 |
Osi Pharm Inc |
KOMPOSISI PIROLO (2,3d) PIRIMIDIN DAN PENGGUNAANNYA
|
US6686366B1
(en)
|
1998-06-02 |
2004-02-03 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A3 receptor and uses thereof
|
US6878716B1
(en)
|
1998-06-02 |
2005-04-12 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A1 receptor and uses thereof
|
UA60365C2
(uk)
|
1998-06-04 |
2003-10-15 |
Пфайзер Продактс Інк. |
Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
|
CA2334545A1
(en)
*
|
1998-06-12 |
1999-12-16 |
Ligand Pharmaceuticals Incorporated |
Treatment of anti-estrogen resistant breast cancer using rxr modulators
|
US6184226B1
(en)
|
1998-08-28 |
2001-02-06 |
Scios Inc. |
Quinazoline derivatives as inhibitors of P-38 α
|
EP1107958B1
(en)
|
1998-08-29 |
2006-08-16 |
AstraZeneca AB |
Pyrimidine compounds
|
JP2002523497A
(ja)
|
1998-08-29 |
2002-07-30 |
アストラゼネカ・アクチエボラーグ |
ピリミジン化合物
|
JP2002523455A
(ja)
|
1998-08-31 |
2002-07-30 |
スージェン・インコーポレーテッド |
蛋白質キナーゼ活性の調節剤としての幾何学的に制限された2−インドリノン誘導体
|
CA2340598A1
(en)
|
1998-09-08 |
2000-03-16 |
Agouron Pharmaceuticals, Inc. |
Modifications of the vegf receptor-2 protein and methods of use
|
US6680335B2
(en)
|
1998-09-28 |
2004-01-20 |
Sugen, Inc. |
Methods of modulating protein tyrosine kinase function with substituted indolinone compounds
|
DK1119567T3
(da)
|
1998-10-08 |
2005-07-25 |
Astrazeneca Ab |
Quinazolinderivater
|
GB9828511D0
(en)
|
1998-12-24 |
1999-02-17 |
Zeneca Ltd |
Chemical compounds
|
EP1630559A3
(en)
*
|
1998-12-30 |
2006-06-07 |
Sugen, Inc. |
PYK2 (RAFTK) and inflammation
|
UA71945C2
(en)
|
1999-01-27 |
2005-01-17 |
Pfizer Prod Inc |
Substituted bicyclic derivatives being used as anticancer agents
|
JP3270834B2
(ja)
|
1999-01-27 |
2002-04-02 |
ファイザー・プロダクツ・インク |
抗がん剤として有用なヘテロ芳香族二環式誘導体
|
EE05345B1
(et)
*
|
1999-02-10 |
2010-10-15 |
Astrazeneca Ab |
Kinasoliini derivaadid angiogeneesi inhibiitoritena
|
GB9905075D0
(en)
|
1999-03-06 |
1999-04-28 |
Zeneca Ltd |
Chemical compounds
|
US6689806B1
(en)
|
1999-03-24 |
2004-02-10 |
Sugen, Inc. |
Indolinone compounds as kinase inhibitors
|
GB9907658D0
(en)
|
1999-04-06 |
1999-05-26 |
Zeneca Ltd |
Chemical compounds
|
GB9910580D0
(en)
|
1999-05-08 |
1999-07-07 |
Zeneca Ltd |
Chemical compounds
|
GB9910579D0
(en)
|
1999-05-08 |
1999-07-07 |
Zeneca Ltd |
Chemical compounds
|
UA71971C2
(en)
|
1999-06-04 |
2005-01-17 |
Agoron Pharmaceuticals Inc |
Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
|
GB9919778D0
(en)
|
1999-08-21 |
1999-10-27 |
Zeneca Ltd |
Chemical compounds
|
US6921763B2
(en)
|
1999-09-17 |
2005-07-26 |
Abbott Laboratories |
Pyrazolopyrimidines as therapeutic agents
|
CN1391561A
(zh)
*
|
1999-09-21 |
2003-01-15 |
阿斯特拉曾尼卡有限公司 |
喹唑啉化合物和含有喹唑啉化合物的药物组合物
|
ATE290865T1
(de)
*
|
1999-10-19 |
2005-04-15 |
Merck & Co Inc |
Tyrosin kinase inhibitoren
|
DE60017179T2
(de)
*
|
1999-10-19 |
2006-01-05 |
Merck & Co., Inc. |
Tyrosin kinaseinhibitoren
|
US6794393B1
(en)
*
|
1999-10-19 |
2004-09-21 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
WO2001031005A2
(en)
|
1999-10-22 |
2001-05-03 |
Pharmacia & Upjohn Company |
Drosophila g protein coupled receptors, nucleic acids, and methods related to the same
|
ES2306306T3
(es)
|
1999-11-05 |
2008-11-01 |
Astrazeneca Ab |
Nuevos derivados de quinazolina.
|
US7087613B2
(en)
|
1999-11-11 |
2006-08-08 |
Osi Pharmaceuticals, Inc. |
Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
|
UA74803C2
(uk)
|
1999-11-11 |
2006-02-15 |
Осі Фармасьютікалз, Інк. |
Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
|
CO5261573A1
(es)
|
1999-11-19 |
2003-03-31 |
Novartis Ag |
Derivados de benzoxa y bezotiazol, compuesto y composicion farmaceutica que los contiene y proceso para la preparacion de la mencionada composicion
|
US6878733B1
(en)
|
1999-11-24 |
2005-04-12 |
Sugen, Inc. |
Formulations for pharmaceutical agents ionizable as free acids or free bases
|
UA75055C2
(uk)
*
|
1999-11-30 |
2006-03-15 |
Пфайзер Продактс Інк. |
Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
|
US7160890B2
(en)
*
|
1999-12-02 |
2007-01-09 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A3 receptor and uses thereof
|
US6680322B2
(en)
|
1999-12-02 |
2004-01-20 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A1 receptors and uses thereof
|
US6664252B2
(en)
|
1999-12-02 |
2003-12-16 |
Osi Pharmaceuticals, Inc. |
4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
|
NZ519697A
(en)
|
1999-12-22 |
2004-08-27 |
Sugen Inc |
Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds
|
AU2001228638A1
(en)
|
2000-01-28 |
2001-08-07 |
Astrazeneca Ab |
Chemical compounds
|
KR20020084116A
(ko)
|
2000-02-07 |
2002-11-04 |
애보트 게엠베하 운트 콤파니 카게 |
2-벤조티아졸릴 우레아 유도체 및 이의 단백질 키나제억제제로서의 용도
|
CZ303705B6
(cs)
*
|
2000-02-15 |
2013-03-27 |
Sugen, Inc. |
Pyrrolem substituovaná 2-indolinonová sloucenina pro pouzití jako inhibitor proteinkináz a farmaceutická kompozice s jejím obsahem
|
US6313138B1
(en)
|
2000-02-25 |
2001-11-06 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
WO2001062252A1
(en)
*
|
2000-02-25 |
2001-08-30 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
US6420382B2
(en)
*
|
2000-02-25 |
2002-07-16 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
EP1259514B9
(en)
|
2000-02-28 |
2005-11-09 |
Sugen, Inc. |
3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors
|
GB0004886D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004890D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004888D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004887D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
US7235551B2
(en)
*
|
2000-03-02 |
2007-06-26 |
Smithkline Beecham Corporation |
1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
|
GB0007371D0
(en)
|
2000-03-28 |
2000-05-17 |
Astrazeneca Uk Ltd |
Chemical compounds
|
US6511984B2
(en)
|
2000-03-30 |
2003-01-28 |
Pfizer Inc. |
Neuropeptide Y antagonists
|
US7160889B2
(en)
*
|
2000-04-07 |
2007-01-09 |
Astrazeneca Ab |
Quinazoline compounds
|
JP2004501083A
(ja)
|
2000-04-18 |
2004-01-15 |
アゴーロン・ファーマシューティカルズ・インコーポレイテッド |
プロテインキナーゼを阻害するためのピラゾール
|
MY128450A
(en)
|
2000-05-24 |
2007-02-28 |
Upjohn Co |
1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
|
WO2001094312A2
(en)
|
2000-06-02 |
2001-12-13 |
Sugen, Inc. |
Indolinone derivatives as protein kinase/phosphatase inhibitors
|
UA73993C2
(uk)
|
2000-06-06 |
2005-10-17 |
Астразенека Аб |
Хіназолінові похідні для лікування пухлин та фармацевтична композиція
|
US6586592B2
(en)
|
2000-06-20 |
2003-07-01 |
Pharmacia & Upjohn Company |
Bis-arylsulfones
|
PE20020063A1
(es)
|
2000-06-20 |
2002-01-30 |
Upjohn Co |
Bis-arilsulfonas como ligandos del receptor de 5-ht
|
PL360439A1
(en)
|
2000-06-28 |
2004-09-06 |
Astrazeneca Ab |
Substituted quinazoline derivatives and their use as inhibitors
|
GB0016877D0
(en)
|
2000-07-11 |
2000-08-30 |
Astrazeneca Ab |
Chemical compounds
|
JP2004505966A
(ja)
|
2000-08-09 |
2004-02-26 |
アストラゼネカ アクチボラグ |
シンノリン化合物
|
BR0113056A
(pt)
|
2000-08-09 |
2003-07-08 |
Astrazeneca Ab |
Composto, processo papa a preparação do mesmo, composição farmacêutica, e, método para produzir um efeito antiangiogênico e/ou redutor da permeabilidade vascular em um animal de sangue quente, e, uso de um composto
|
CA2426440C
(en)
|
2000-08-18 |
2011-03-15 |
Millennium Pharmaceuticals, Inc. |
Quinazoline derivatives as kinase inhibitors
|
EP1313727A1
(en)
|
2000-08-21 |
2003-05-28 |
AstraZeneca AB |
Quinazoline derivatives
|
ATE448226T1
(de)
|
2000-09-01 |
2009-11-15 |
Novartis Vaccines & Diagnostic |
Aza heterocyclische derivate und ihre therapeutische verwendung
|
GB0021726D0
(en)
|
2000-09-05 |
2000-10-18 |
Astrazeneca Ab |
Chemical compounds
|
ATE309996T1
(de)
|
2000-09-11 |
2005-12-15 |
Chiron Corp |
Chinolinonderivate als tyrosin-kinase inhibitoren
|
FR2813791B1
(fr)
*
|
2000-09-14 |
2004-03-12 |
Lafon Labor |
Utilisation de 2- et 4-quinolones pour inhiber la neo-proliferation intimale
|
US6849625B2
(en)
|
2000-10-13 |
2005-02-01 |
Astrazeneca Ab |
Quinazoline derivatives with anti-tumour activity
|
JP2004511480A
(ja)
|
2000-10-13 |
2004-04-15 |
アストラゼネカ アクチボラグ |
キナゾリン誘導体
|
ATE303998T1
(de)
*
|
2000-10-17 |
2005-09-15 |
Merck & Co Inc |
Oral aktive salze mit tyrosinkinaseaktivität
|
EP1415987B1
(en)
|
2000-10-20 |
2007-02-28 |
Eisai R&D Management Co., Ltd. |
Nitrogenous aromatic ring compounds as anti cancer agents
|
NZ524806A
(en)
*
|
2000-10-23 |
2006-03-31 |
Smithkline Beecham Corp |
Tri-substituted 8H-pyrido[2,3-d]pyrimidin-7-one compounds
|
WO2002036587A2
(en)
|
2000-11-01 |
2002-05-10 |
Cor Therapeutics, Inc. |
Process for the production of 4-quinazolinylpiperazin-1-carboxylic acid phenylamides
|
US7253184B2
(en)
*
|
2000-11-02 |
2007-08-07 |
Astrazeneca Ab |
4-Substituted quinolines as antitumor agents
|
AU2002210714A1
(en)
*
|
2000-11-02 |
2002-06-11 |
Astrazeneca Ab |
Substituted quinolines as antitumor agents
|
US6673802B2
(en)
|
2000-12-01 |
2004-01-06 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A3 receptor and uses thereof
|
US6582919B2
(en)
|
2001-06-11 |
2003-06-24 |
Response Genetics, Inc. |
Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates
|
US6680324B2
(en)
*
|
2000-12-01 |
2004-01-20 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A1 receptors and uses thereof
|
AR042586A1
(es)
|
2001-02-15 |
2005-06-29 |
Sugen Inc |
3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
|
GB0103926D0
(en)
|
2001-02-17 |
2001-04-04 |
Astrazeneca Ab |
Chemical compounds
|
MXPA03008560A
(es)
|
2001-03-22 |
2004-06-30 |
Abbot Gmbh & Co Kg |
Pirazolopirimidinas como agentes terapeuticos.
|
DE60229046D1
(de)
|
2001-04-19 |
2008-11-06 |
Astrazeneca Ab |
Chinazolin derivate
|
GB0113041D0
(en)
|
2001-05-30 |
2001-07-18 |
Astrazeneca Ab |
Chemical compounds
|
PE20030062A1
(es)
|
2001-05-30 |
2003-02-08 |
Sugen Inc |
Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas
|
AU2002350105A1
(en)
|
2001-06-21 |
2003-01-08 |
Ariad Pharmaceuticals, Inc. |
Novel quinazolines and uses thereof
|
US8124625B2
(en)
*
|
2001-09-14 |
2012-02-28 |
Shionogi & Co., Ltd. |
Method of enhancing the expression of apolipoprotein AI using olefin derivatives
|
US6559173B1
(en)
|
2001-09-27 |
2003-05-06 |
Allergan, Inc. |
3-(heteroarylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
|
US20030225152A1
(en)
|
2001-09-27 |
2003-12-04 |
Andrews Steven W. |
3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors
|
CA2462950A1
(en)
|
2001-10-10 |
2003-04-17 |
Sugen, Inc. |
3-[4-(substituted heterocyclyl)-pyrrol-2-ylmethylidene]-2-indolinone derivatives as kinase inhibitors
|
AU2002361577A1
(en)
*
|
2001-10-30 |
2003-05-12 |
Merck And Co., Inc. |
Tyrosine kinase inhibitors
|
WO2003048120A2
(en)
*
|
2001-11-30 |
2003-06-12 |
Osi Pharmaceuticals, Inc. |
2-aryl pyrrologpyrimidines for a1 and a3 receptors
|
US6916804B2
(en)
|
2001-12-20 |
2005-07-12 |
Osi Pharmaceuticals, Inc. |
Pyrimidine A2b selective antagonist compounds, their synthesis and use
|
US20030229067A1
(en)
*
|
2001-12-20 |
2003-12-11 |
Arlindo Castelhano |
Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use
|
IL162541A0
(en)
|
2001-12-24 |
2005-11-20 |
Astrazeneca Ab |
Substituted quinazoline derivatives as inhibitors of aurora kinases
|
KR20060111716A
(ko)
|
2002-01-22 |
2006-10-27 |
워너-램버트 캄파니 엘엘씨 |
2-(피리딘-2-일아미노)-피리도[2,3-d]피리미딘-7-온
|
UA81619C2
(ru)
*
|
2002-02-01 |
2008-01-25 |
Астразенека Аб |
Хиназолиновые соединения, способ их получения (варианты), фармацевтическая композиция на их основе
|
GB0205693D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
GB0205688D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
GB0205690D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
WO2003076434A1
(en)
|
2002-03-09 |
2003-09-18 |
Astrazeneca Ab |
4- imidazolyl substuited pyrimidine derivatives with cdk inhibitiory activity
|
JP2005531520A
(ja)
|
2002-03-28 |
2005-10-20 |
メルク エンド カムパニー インコーポレーテッド |
置換2,3−ジフェニルピリジン類
|
US6924285B2
(en)
|
2002-03-30 |
2005-08-02 |
Boehringer Ingelheim Pharma Gmbh & Co. |
Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
|
US6541504B1
(en)
|
2002-04-03 |
2003-04-01 |
Allergan Sales, Llc |
(3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
|
RU2004133811A
(ru)
*
|
2002-04-19 |
2005-04-20 |
Смитклайн Бичам Корпорейшн (US) |
Новые соединения
|
EA008770B1
(ru)
*
|
2002-05-15 |
2007-08-31 |
Янссен Фамацевтика Н.В. |
N-замещенные трициклические 3-аминопиразолы в качестве ингибиторов pdgf рецептора
|
GB0215823D0
(en)
*
|
2002-07-09 |
2002-08-14 |
Astrazeneca Ab |
Quinazoline derivatives
|
EP1528925B1
(en)
*
|
2002-07-09 |
2009-04-22 |
Astrazeneca AB |
Quinazoline derivatives for use in the treatment of cancer
|
US7514468B2
(en)
|
2002-07-23 |
2009-04-07 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions
|
US7169936B2
(en)
|
2002-07-23 |
2007-01-30 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
|
EP1527071A1
(en)
|
2002-07-25 |
2005-05-04 |
Pfizer Products Inc. |
Isothiazole derivatives useful as anticancer agents
|
CA2494061C
(en)
*
|
2002-07-31 |
2011-06-14 |
Wayne R. Danter |
Protein tyrosine kinase inhibitors
|
US8450302B2
(en)
|
2002-08-02 |
2013-05-28 |
Ab Science |
2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
|
JP4726486B2
(ja)
|
2002-08-02 |
2011-07-20 |
アブ サイエンス |
2−(3−アミノアリール)アミノ−4−アリール−チアゾールおよびそれらのc−kit阻害薬としての使用法
|
US7825132B2
(en)
|
2002-08-23 |
2010-11-02 |
Novartis Vaccines And Diagnostics, Inc. |
Inhibition of FGFR3 and treatment of multiple myeloma
|
EP1539754A4
(en)
|
2002-08-23 |
2009-02-25 |
Novartis Vaccines & Diagnostic |
BENZIMIDAZOLE QUINOLINONES AND USES THEREOF
|
US7629347B2
(en)
*
|
2002-10-09 |
2009-12-08 |
Critical Outcome Technologies, Inc. |
Protein tyrosine kinase inhibitors
|
GB0225548D0
(en)
|
2002-11-01 |
2002-12-11 |
Glaxo Group Ltd |
Compounds
|
GB0225579D0
(en)
*
|
2002-11-02 |
2002-12-11 |
Astrazeneca Ab |
Chemical compounds
|
WO2004041755A2
(en)
*
|
2002-11-04 |
2004-05-21 |
Nps Pharmaceuticals, Inc. |
Quinazolinone compounds as calcilytics
|
KR101089462B1
(ko)
|
2002-11-04 |
2011-12-07 |
아스트라제네카 아베 |
Src 티로신 키나제 억제제로서의 퀴나졸린 유도체
|
EP1575575B1
(en)
*
|
2002-11-08 |
2010-05-19 |
High Point Pharmaceuticals, LLC |
Safe chemical uncouplers for the treatment of obesity
|
WO2004043389A2
(en)
|
2002-11-13 |
2004-05-27 |
Chiron Corporation |
Methods of treating cancer and related methods
|
US6699863B1
(en)
|
2002-11-27 |
2004-03-02 |
Allergan, Inc. |
Kinase inhibitors for the treatment of disease
|
US6747025B1
(en)
|
2002-11-27 |
2004-06-08 |
Allergan, Inc. |
Kinase inhibitors for the treatment of disease
|
EP1625121B1
(en)
|
2002-12-20 |
2010-02-24 |
Pfizer Products Inc. |
Pyrimidine derivatives for the treatment of abnormal cell growth
|
ES2290529T3
(es)
|
2002-12-24 |
2008-02-16 |
Astrazeneca Ab |
Derivados de fosfonooxiquinazolina y su uso farmaceutico.
|
AU2004212957A1
(en)
*
|
2003-02-14 |
2004-09-02 |
Smithkline Beecham Corporation |
Novel compounds
|
NZ541861A
(en)
*
|
2003-02-26 |
2009-05-31 |
Sugen Inc |
Aminoheteroaryl compounds as protein kinase inhibitors
|
US7157577B2
(en)
|
2003-03-07 |
2007-01-02 |
Sugen Inc. |
5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors
|
GB0309850D0
(en)
|
2003-04-30 |
2003-06-04 |
Astrazeneca Ab |
Quinazoline derivatives
|
GB0311274D0
(en)
|
2003-05-16 |
2003-06-18 |
Astrazeneca Ab |
Chemical compounds
|
GB0311276D0
(en)
|
2003-05-16 |
2003-06-18 |
Astrazeneca Ab |
Chemical compounds
|
KR101099409B1
(ko)
|
2003-06-06 |
2011-12-27 |
아렉시스 악티에볼라그 |
피부 상태 또는 암 치료를 위한 scce 저해제로서의융합된 헤테로사이클 화합물의 용도
|
WO2006074147A2
(en)
|
2005-01-03 |
2006-07-13 |
Myriad Genetics, Inc. |
Nitrogen containing bicyclic compounds and therapeutical use thereof
|
EP1660092A2
(en)
*
|
2003-07-03 |
2006-05-31 |
Myriad Genetics, Inc. |
4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
|
US8309562B2
(en)
|
2003-07-03 |
2012-11-13 |
Myrexis, Inc. |
Compounds and therapeutical use thereof
|
GB0317665D0
(en)
|
2003-07-29 |
2003-09-03 |
Astrazeneca Ab |
Qinazoline derivatives
|
US7105562B2
(en)
|
2003-08-06 |
2006-09-12 |
Sugen, Inc. |
Geometrically restricted 3-cyclopentylidene-1,3-dihydroindol-2-ones as potent protein tyrosine kinase inhibitors
|
DK1660057T3
(da)
|
2003-08-27 |
2012-08-20 |
Ophthotech Corp |
Kombinationsterapi til behandling af neovaskulære øjenlidelser
|
JP4795952B2
(ja)
|
2003-09-16 |
2011-10-19 |
アストラゼネカ アクチボラグ |
チロシンキナーゼ阻害剤としてのキナゾリン誘導体
|
DE602004004553T2
(de)
|
2003-09-19 |
2007-10-25 |
Astrazeneca Ab |
Chinazolinderivate
|
DE602004019135D1
(de)
*
|
2003-10-07 |
2009-03-05 |
Centelion |
Screeningverfahren für Kombinationen von biologischen Verbindungen
|
NZ546645A
(en)
|
2003-10-23 |
2010-02-26 |
Ab Science |
2-Aminoaryloxazole compounds as tyrosine kinase inhibitors
|
JP4303726B2
(ja)
|
2003-11-11 |
2009-07-29 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
ウレア誘導体およびその製造方法
|
GB0326459D0
(en)
|
2003-11-13 |
2003-12-17 |
Astrazeneca Ab |
Quinazoline derivatives
|
JP2007511514A
(ja)
*
|
2003-11-13 |
2007-05-10 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
生体分子標的同定用の固定化n置換三環状3−アミノピラゾール
|
GB0330002D0
(en)
|
2003-12-24 |
2004-01-28 |
Astrazeneca Ab |
Quinazoline derivatives
|
TW200528101A
(en)
|
2004-02-03 |
2005-09-01 |
Astrazeneca Ab |
Chemical compounds
|
BRPI0400869B8
(pt)
*
|
2004-03-02 |
2021-05-25 |
Univ Estadual Campinas Unicamp |
novos compostos derivados de 4-anilinoquinazolinas com propriedade inibidora de adenosinacinases
|
CN1960731B
(zh)
|
2004-02-20 |
2011-12-07 |
诺华疫苗和诊断公司 |
调节炎性和转移过程的方法
|
EP2168968B1
(en)
|
2004-04-02 |
2017-08-23 |
OSI Pharmaceuticals, LLC |
6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
|
US20070254877A1
(en)
*
|
2004-06-02 |
2007-11-01 |
Takada Pharmaceutical Company Limited |
Indole Derivative and Use for Treatment of Cancer
|
TW200613306A
(en)
|
2004-07-20 |
2006-05-01 |
Osi Pharm Inc |
Imidazotriazines as protein kinase inhibitors
|
JP4834553B2
(ja)
|
2004-09-17 |
2011-12-14 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
医薬組成物
|
US20070197538A1
(en)
*
|
2004-10-07 |
2007-08-23 |
Mark Nesbit |
Anti-vascular and anti-proliferation methods, therapies, and combinations employing specific tyrosine kinase inhibitors
|
CN101072758B
(zh)
|
2004-10-12 |
2013-07-31 |
阿斯利康(瑞典)有限公司 |
喹唑啉衍生物
|
EP2332527A3
(en)
|
2004-10-20 |
2011-11-16 |
Resverlogix Corp. |
Flavanoids and Isoflavanoids for the prevention and treatment of cardiovascular diseases
|
DE602005026865D1
(de)
|
2004-12-14 |
2011-04-21 |
Astrazeneca Ab |
Pyrazolopyrimidinverbindungen als antitumormittel
|
US8258145B2
(en)
*
|
2005-01-03 |
2012-09-04 |
Myrexis, Inc. |
Method of treating brain cancer
|
JP4137174B2
(ja)
|
2005-02-23 |
2008-08-20 |
塩野義製薬株式会社 |
チロシンキナーゼ阻害作用を有するキナゾリン誘導体
|
AU2006217738A1
(en)
|
2005-02-26 |
2006-08-31 |
Astrazeneca Ab |
Quinazoline derivatives as tyrosine kinase inhibitors
|
CN101166730A
(zh)
|
2005-03-01 |
2008-04-23 |
惠氏公司 |
噌啉化合物及其作为肝x受体调节剂的用途
|
WO2006104917A2
(en)
*
|
2005-03-25 |
2006-10-05 |
Glaxo Group Limited |
Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1h)-one derivatives
|
JP2008535822A
(ja)
*
|
2005-03-25 |
2008-09-04 |
グラクソ グループ リミテッド |
新規化合物
|
UY29440A1
(es)
|
2005-03-25 |
2006-10-02 |
Glaxo Group Ltd |
Nuevos compuestos
|
PE20061193A1
(es)
*
|
2005-03-25 |
2006-12-02 |
Glaxo Group Ltd |
DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2-[1H]-0NA COMO INHIBIDORES DE QUINASA p38
|
UA95071C2
(ru)
|
2005-04-04 |
2011-07-11 |
Аб Сьянс |
Замещенные производные оксазола и их применение как ингибиторов тирозинкиназы
|
PT1928454E
(pt)
|
2005-05-10 |
2014-12-04 |
Intermune Inc |
Derivativos da piridona para modulação do sistema de proteína quinase ativada pelo stress
|
JP5344910B2
(ja)
|
2005-05-13 |
2013-11-20 |
ノバルティス アーゲー |
薬剤耐性癌の処置方法
|
BRPI0610355A2
(pt)
|
2005-05-17 |
2010-06-15 |
Novartis Ag |
métodos par sintetizar compostos heterocìclicos
|
WO2006127926A2
(en)
|
2005-05-23 |
2006-11-30 |
Novartis Ag |
Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts
|
KR101431279B1
(ko)
|
2005-07-29 |
2014-08-20 |
리스버로직스 코퍼레이션 |
복합 질환의 예방 및 치료용 약학적 조성물 및 삽입가능한의료 장치에 의한 이의 전달
|
JP4989476B2
(ja)
|
2005-08-02 |
2012-08-01 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
血管新生阻害物質の効果を検定する方法
|
US7709468B2
(en)
|
2005-09-02 |
2010-05-04 |
Abbott Laboratories |
Imidazo based heterocycles
|
US7820683B2
(en)
|
2005-09-20 |
2010-10-26 |
Astrazeneca Ab |
4-(1H-indazol-5-yl-amino)-quinazoline compounds as erbB receptor tyrosine kinase inhibitors for the treatment of cancer
|
US20080003219A1
(en)
*
|
2005-09-26 |
2008-01-03 |
Minu, L.L.C. |
Delivery of an ocular agent
|
CA2623374A1
(en)
|
2005-09-30 |
2007-04-05 |
Astrazeneca Ab |
Imidazo [1,2-a] pyridine having anti-cell-proliferation activity
|
GB0519879D0
(en)
|
2005-09-30 |
2005-11-09 |
Astrazeneca Ab |
Chemical process
|
AR057960A1
(es)
|
2005-12-02 |
2007-12-26 |
Osi Pharm Inc |
Inhibidores de proteina quinasa biciclicos
|
US7465795B2
(en)
|
2005-12-20 |
2008-12-16 |
Astrazeneca Ab |
Compounds and uses thereof
|
ES2391472T3
(es)
|
2005-12-20 |
2012-11-27 |
Astrazeneca Ab |
Derivados de cinnolina sustituidos como moduladores del receptor de GABAA y método para su síntesis
|
US8338415B2
(en)
|
2006-01-24 |
2012-12-25 |
Allergan, Inc. |
Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-one's and derivatives thereof as kinase inhibitors
|
UY30183A1
(es)
|
2006-03-02 |
2007-10-31 |
Astrazeneca Ab |
Derivados de quinolina
|
US7977351B2
(en)
|
2006-03-22 |
2011-07-12 |
Allergan, Inc. |
Heteroaryl dihydroindolones as kinase inhibitors
|
WO2007132307A1
(en)
|
2006-05-09 |
2007-11-22 |
Pfizer Products Inc. |
Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
|
JP5190361B2
(ja)
|
2006-05-18 |
2013-04-24 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
甲状腺癌に対する抗腫瘍剤
|
CN101100466B
(zh)
|
2006-07-05 |
2013-12-25 |
天津和美生物技术有限公司 |
不可逆蛋白质酪氨酸磷酰化酶抑制剂及其制备和应用
|
US8246966B2
(en)
|
2006-08-07 |
2012-08-21 |
University Of Georgia Research Foundation, Inc. |
Trypanosome microsome system and uses thereof
|
US8865737B2
(en)
|
2006-08-28 |
2014-10-21 |
Eisai R&D Management Co., Ltd. |
Antitumor agent for undifferentiated gastric cancer
|
AU2007303846B2
(en)
*
|
2006-10-04 |
2011-03-10 |
Pfizer Products Inc. |
Pyrido[4,3-d]pyrimidin-4(3H)-one derivatives as calcium receptor antagonists
|
EP1921070A1
(de)
|
2006-11-10 |
2008-05-14 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
|
JP2010510242A
(ja)
|
2006-11-16 |
2010-04-02 |
アラーガン、インコーポレイテッド |
キナーゼ阻害剤としてのスルホキシミン
|
US8558002B2
(en)
|
2006-11-16 |
2013-10-15 |
Allergan, Inc. |
Sulfoximines as kinase inhibitors
|
CA2669531A1
(en)
|
2006-11-22 |
2008-06-05 |
University Of Georgia Research Foundation, Inc. |
Tyrosine kinase inhibitors as anti-kinetolastid and anti-apicomplexan agents
|
WO2008083491A1
(en)
|
2007-01-11 |
2008-07-17 |
Critical Outcome Technologies Inc. |
Compounds and method for treatment of cancer
|
AU2008211952B2
(en)
|
2007-01-29 |
2012-07-19 |
Eisai R & D Management Co., Ltd. |
Composition for treatment of undifferentiated-type of gastric cancer
|
PL2118074T3
(pl)
|
2007-02-01 |
2014-06-30 |
Resverlogix Corp |
Związki chemiczne do celów profilaktyki i leczenia chorób układu sercowo-naczyniowego
|
WO2008095847A1
(de)
|
2007-02-06 |
2008-08-14 |
Boehringer Ingelheim International Gmbh |
Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
|
US20080190689A1
(en)
*
|
2007-02-12 |
2008-08-14 |
Ballard Ebbin C |
Inserts for engine exhaust systems
|
EP2146740A4
(en)
|
2007-04-13 |
2010-05-26 |
Agency Science Tech & Res |
METHODS OF COMBATING ONCOGENESIS AND DIAGNOSING THE RISK OF APPEARANCE THEREOF
|
UA97834C2
(ru)
|
2007-04-18 |
2012-03-26 |
Пфайзер Продактс Инк. |
Производные сульфониламида для лечения анормального роста клеток
|
CL2008001356A1
(es)
*
|
2007-05-10 |
2008-11-14 |
Smithkline Beecham Corp |
Compuestos derivados de quinoxalina, inhibidores de la pi3 quinasa _(p13ka, pi3ko, pi3b y/o pi3ky); composicion farmaceutica; uso para tratar un trastorno autoinmune, enfermedad inflamatoria, cardiovascular, neurodegerativa, alergia, asma, enfermedad renal, cancer, rechazo de transplante, lesiones pulmonares.
|
EP2170805B1
(en)
|
2007-06-21 |
2016-03-16 |
Amgen Inc. |
Methods of synthesizing cinacalcet and salts thereof
|
US8080558B2
(en)
|
2007-10-29 |
2011-12-20 |
Natco Pharma Limited |
4-(tetrazol-5-yl)-quinazoline derivatives as anti-cancer agent
|
WO2009058102A1
(en)
|
2007-11-02 |
2009-05-07 |
Agency For Science, Technology And Research |
Methods and compounds for preventing and treating a tumour
|
KR101513326B1
(ko)
|
2007-11-09 |
2015-04-17 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
혈관 신생 저해 물질과 항종양성 백금 착물의 병용
|
EP2225226B1
(en)
*
|
2007-12-26 |
2016-08-17 |
Critical Outcome Technologies, Inc. |
Compounds and their use in a method for treatment of cancer
|
KR101897881B1
(ko)
|
2008-01-04 |
2018-09-12 |
인텔리카인, 엘엘씨 |
특정 화학 물질, 조성물 및 방법
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
AU2009211523B2
(en)
|
2008-02-07 |
2014-03-13 |
Boehringer Ingelheim International Gmbh |
Spirocyclic heterocycles, medicaments containing said compounds, use thereof and method for their production
|
JP5739802B2
(ja)
|
2008-05-13 |
2015-06-24 |
アストラゼネカ アクチボラグ |
4−(3−クロロ−2−フルオロアニリノ)−7−メトキシ−6−{[1−(n−メチルカルバモイルメチル)ピペリジン−4−イル]オキシ}キナゾリンのフマル酸塩
|
JP5627574B2
(ja)
|
2008-06-03 |
2014-11-19 |
インターミューン, インコーポレイテッド |
炎症性および線維性疾患を治療するための化合物および方法
|
NZ586440A
(en)
|
2008-06-26 |
2011-07-29 |
Resverlogix Corp |
Methods of preparing quinazolinone derivatives
|
WO2010006438A1
(en)
|
2008-07-17 |
2010-01-21 |
Critical Outcome Technologies Inc. |
Thiosemicarbazone inhibitor compounds and cancer treatment methods
|
CA2733153C
(en)
|
2008-08-08 |
2016-11-08 |
Boehringer Ingelheim International Gmbh |
Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
|
MX2011003239A
(es)
|
2008-09-26 |
2011-04-28 |
Merck Sharp & Dohme |
Nuevos derivados de bencimidazol ciclicos utiles como agentes anti-diabeticos.
|
EP2348857B1
(en)
|
2008-10-22 |
2016-02-24 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
MX2011004505A
(es)
|
2008-10-29 |
2011-05-31 |
Merck Sharp & Dohme |
Derivados novedosos de bencimidazol ciclico, utiles como agentes antidiabeticos.
|
CA2741672A1
(en)
|
2008-10-31 |
2010-05-06 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
CA2742986C
(en)
|
2008-11-07 |
2015-03-31 |
Triact Therapeutics, Inc. |
Use of catecholic butane derivatives in cancer therapy
|
ES2463097T3
(es)
|
2009-01-08 |
2014-05-27 |
Resverlogix Corp. |
Compuestos para la prevención y el tratamiento de enfermedades cardiovasculares
|
US20120189641A1
(en)
|
2009-02-25 |
2012-07-26 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
EP2400990A2
(en)
|
2009-02-26 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
In situ methods for monitoring the emt status of tumor cells in vivo
|
EP2401614A1
(en)
|
2009-02-27 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
US8465912B2
(en)
|
2009-02-27 |
2013-06-18 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
US9238640B2
(en)
|
2009-03-18 |
2016-01-19 |
Resverlogix Corp. |
Anti-inflammatory agents
|
US20120064072A1
(en)
|
2009-03-18 |
2012-03-15 |
Maryland Franklin |
Combination Cancer Therapy Comprising Administration of an EGFR Inhibitor and an IGF-1R Inhibitor
|
NZ596117A
(en)
*
|
2009-04-22 |
2014-10-31 |
Resverlogix Corp |
Novel anti-inflammatory agents
|
SG176628A1
(en)
|
2009-06-05 |
2012-01-30 |
Link Medicine Corp |
Aminopyrrolidinone derivatives and uses thereof
|
WO2011027249A2
(en)
|
2009-09-01 |
2011-03-10 |
Pfizer Inc. |
Benzimidazole derivatives
|
US9340555B2
(en)
|
2009-09-03 |
2016-05-17 |
Allergan, Inc. |
Compounds as tyrosine kinase modulators
|
MX2012002591A
(es)
|
2009-09-03 |
2012-04-02 |
Allergan Inc |
Compuestos como moduladores de tirosina cinasas.
|
US20120316187A1
(en)
|
2009-11-13 |
2012-12-13 |
Pangaea Biotech, S.L. |
Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
|
US8895596B2
(en)
|
2010-02-25 |
2014-11-25 |
Merck Sharp & Dohme Corp |
Cyclic benzimidazole derivatives useful as anti-diabetic agents
|
WO2011120153A1
(en)
|
2010-04-01 |
2011-10-06 |
Critical Outcome Technologies Inc. |
Compounds and method for treatment of hiv
|
WO2011153049A1
(en)
|
2010-06-02 |
2011-12-08 |
The Trustees Of The University Of Pennsylvania |
Methods and use of compounds that bind to her2/neu receptor complex
|
WO2011153050A1
(en)
|
2010-06-02 |
2011-12-08 |
The Trustees Of The University Of Pennsylvania |
Methods and use of compounds that bind to her2/neu receptor complex
|
EP2580320B1
(en)
|
2010-06-14 |
2018-08-01 |
The Scripps Research Institute |
Reprogramming of cells to a new fate
|
CA2802644C
(en)
|
2010-06-25 |
2017-02-21 |
Eisai R & D Management Co., Ltd. |
Antitumor agent using compounds having kinase inhibitory effect in combination
|
RS55856B1
(sr)
|
2010-07-14 |
2017-08-31 |
Novartis Ag |
Heterociklična jedinjenja agonisti ip receptora
|
JP5802756B2
(ja)
|
2010-10-20 |
2015-11-04 |
ファイザー・インク |
スムーズンド受容体モジュレーターとしてのピリジン−2−誘導体
|
EP2468883A1
(en)
|
2010-12-22 |
2012-06-27 |
Pangaea Biotech S.L. |
Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
|
US8809349B2
(en)
|
2011-01-10 |
2014-08-19 |
Infinity Pharmaceuticals, Inc. |
Processes for preparing isoquinolinones and solid forms of isoquinolinones
|
US9134297B2
(en)
|
2011-01-11 |
2015-09-15 |
Icahn School Of Medicine At Mount Sinai |
Method and compositions for treating cancer and related methods
|
EP2492688A1
(en)
|
2011-02-23 |
2012-08-29 |
Pangaea Biotech, S.A. |
Molecular biomarkers for predicting response to antitumor treatment in lung cancer
|
WO2012129145A1
(en)
|
2011-03-18 |
2012-09-27 |
OSI Pharmaceuticals, LLC |
Nscle combination therapy
|
CA2828946C
(en)
|
2011-04-18 |
2016-06-21 |
Eisai R&D Management Co., Ltd. |
Therapeutic agent for tumor
|
WO2012149014A1
(en)
|
2011-04-25 |
2012-11-01 |
OSI Pharmaceuticals, LLC |
Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
|
US9945862B2
(en)
|
2011-06-03 |
2018-04-17 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
|
WO2013003538A1
(en)
*
|
2011-06-30 |
2013-01-03 |
Angus Chemical Company |
Biphenol ether compounds
|
CN104024432B
(zh)
|
2011-08-31 |
2017-02-22 |
基因泰克公司 |
诊断性标志物
|
BR112014006840A2
(pt)
|
2011-09-22 |
2017-04-04 |
Pfizer |
derivados de pirrolopirimidina e purina
|
JP2014531213A
(ja)
|
2011-09-30 |
2014-11-27 |
ジェネンテック, インコーポレイテッド |
上皮又は間葉の表現型の診断用メチル化マーカー、及び腫瘍又は腫瘍細胞におけるegfrキナーゼ阻害薬に対する応答
|
HUE044986T2
(hu)
|
2011-11-01 |
2019-11-28 |
Resverlogix Corp |
Orális, azonnali felszabadulású készítmények szubsztituált kinazolinonokhoz
|
ES2565826T3
(es)
|
2012-01-13 |
2016-04-07 |
Novartis Ag |
Pirroles fusionados como agonistas del receptor IP para el tratamiento de hipertensión arterial pulmonar (PAH) y trastornos relacionados
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
WO2013190089A1
(en)
|
2012-06-21 |
2013-12-27 |
Pangaea Biotech, S.L. |
Molecular biomarkers for predicting outcome in lung cancer
|
US8828998B2
(en)
|
2012-06-25 |
2014-09-09 |
Infinity Pharmaceuticals, Inc. |
Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
|
US9637523B2
(en)
|
2012-08-31 |
2017-05-02 |
Westfaelische Wilhelms-Universitaet Muenster |
Methods and peptides for preventing and treating a BCR-ABL and a C-ABL associated disease
|
AR092742A1
(es)
|
2012-10-02 |
2015-04-29 |
Intermune Inc |
Piridinonas antifibroticas
|
KR20150070348A
(ko)
|
2012-10-16 |
2015-06-24 |
얀센 파마슈티카 엔.브이. |
RoRγt의 헤테로아릴 결합 퀴놀리닐 조절제
|
CN105073729A
(zh)
|
2012-10-16 |
2015-11-18 |
詹森药业有限公司 |
RORγt的苯基连接的喹啉基调节剂
|
PL2909192T3
(pl)
|
2012-10-16 |
2017-09-29 |
Janssen Pharmaceutica Nv |
Połączone metylenem modulatory chinolinylowe ROR-GAMMA-T
|
WO2014080290A2
(en)
|
2012-11-21 |
2014-05-30 |
Rvx Therapeutics Inc. |
Cyclic amines as bromodomain inhibitors
|
US9765039B2
(en)
|
2012-11-21 |
2017-09-19 |
Zenith Epigenetics Ltd. |
Biaryl derivatives as bromodomain inhibitors
|
WO2014098176A1
(ja)
|
2012-12-21 |
2014-06-26 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
キノリン誘導体のアモルファス及びその製造方法
|
KR20150096794A
(ko)
|
2012-12-21 |
2015-08-25 |
제니쓰 에피제네틱스 코포레이션 |
브로모도메인 저해제로서의 신규한 헤테로사이클릭 화합물
|
JP2016507582A
(ja)
|
2013-02-13 |
2016-03-10 |
ノバルティス アーゲー |
Ip受容体アゴニスト複素環式化合物
|
EP2961412A4
(en)
|
2013-02-26 |
2016-11-09 |
Triact Therapeutics Inc |
CANCER THERAPY
|
US9468681B2
(en)
|
2013-03-01 |
2016-10-18 |
California Institute Of Technology |
Targeted nanoparticles
|
US20160051556A1
(en)
|
2013-03-21 |
2016-02-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method and Pharmaceutical Composition for use in the Treatment of Chronic Liver Diseases Associated with a Low Hepcidin Expression
|
KR102204279B1
(ko)
|
2013-05-14 |
2021-01-15 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
자궁내막암 대상의 렌바티닙 화합물에 대한 반응성을 예측 및 평가하기 위한 생체표지
|
US9381246B2
(en)
|
2013-09-09 |
2016-07-05 |
Triact Therapeutics, Inc. |
Cancer therapy
|
WO2015036792A1
(en)
|
2013-09-16 |
2015-03-19 |
Astrazeneca Ab |
Therapeutic polymeric nanoparticles and methods of making and using same
|
US9751888B2
(en)
|
2013-10-04 |
2017-09-05 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
JP6466924B2
(ja)
|
2013-10-04 |
2019-02-06 |
インフィニティー ファーマシューティカルズ, インコーポレイテッド |
複素環式化合物及びその使用
|
US9284308B2
(en)
|
2013-10-15 |
2016-03-15 |
Janssen Pharmaceutica Nv |
Methylene linked quinolinyl modulators of RORγt
|
US9221804B2
(en)
|
2013-10-15 |
2015-12-29 |
Janssen Pharmaceutica Nv |
Secondary alcohol quinolinyl modulators of RORγt
|
US9403816B2
(en)
|
2013-10-15 |
2016-08-02 |
Janssen Pharmaceutica Nv |
Phenyl linked quinolinyl modulators of RORγt
|
US9328095B2
(en)
|
2013-10-15 |
2016-05-03 |
Janssen Pharmaceutica Nv |
Heteroaryl linked quinolinyl modulators of RORgammat
|
WO2015057626A1
(en)
|
2013-10-15 |
2015-04-23 |
Janssen Pharmaceutica Nv |
QUINOLINYL MODULATORS OF RORyT
|
US10555941B2
(en)
|
2013-10-15 |
2020-02-11 |
Janssen Pharmaceutica Nv |
Alkyl linked quinolinyl modulators of RORγt
|
WO2015057629A1
(en)
*
|
2013-10-15 |
2015-04-23 |
Janssen Pharmaceutica Nv |
ALKYL LINKED QUINOLINYL MODULATORS OF RORyt
|
UA115388C2
(uk)
|
2013-11-21 |
2017-10-25 |
Пфайзер Інк. |
2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
|
DK3119397T3
(da)
|
2014-03-19 |
2022-03-28 |
Infinity Pharmaceuticals Inc |
Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser
|
CA2943363A1
(en)
|
2014-04-02 |
2015-10-08 |
Intermune, Inc. |
Anti-fibrotic pyridinones
|
WO2015156674A2
(en)
|
2014-04-10 |
2015-10-15 |
Stichting Het Nederlands Kanker Instituut |
Method for treating cancer
|
WO2015155624A1
(en)
|
2014-04-10 |
2015-10-15 |
Pfizer Inc. |
Dihydropyrrolopyrimidine derivatives
|
WO2015160975A2
(en)
|
2014-04-16 |
2015-10-22 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
RS59617B1
(sr)
|
2014-04-30 |
2020-01-31 |
Pfizer |
Cikloalkil-vezani diheterociklični derivati
|
WO2016001789A1
(en)
|
2014-06-30 |
2016-01-07 |
Pfizer Inc. |
Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
|
MX2017001980A
(es)
|
2014-08-28 |
2017-05-04 |
Eisai R&D Man Co Ltd |
Derivado de quinolina muy puro y metodo para su produccion.
|
WO2016054491A1
(en)
|
2014-10-03 |
2016-04-07 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
JP6622210B2
(ja)
*
|
2014-11-07 |
2019-12-18 |
サンアプロ株式会社 |
スルホネート化合物、光酸発生剤及びフォトリソグラフィー用樹脂組成物
|
SG11201704852SA
(en)
|
2014-12-24 |
2017-07-28 |
Genentech Inc |
Therapeutic, diagnostic and prognostic methods for cancer of the bladder
|
EA201791781A1
(ru)
|
2015-02-11 |
2018-02-28 |
Базилеа Фармацойтика Интернациональ Аг |
Производные замещенного моно- и полиазанафталина и их применение
|
BR112017017428A2
(pt)
|
2015-02-25 |
2018-04-03 |
Eisai R&D Management Co., Ltd. |
?método para supressão do amargor de derivado de quinolina?
|
KR102662228B1
(ko)
|
2015-03-04 |
2024-05-02 |
머크 샤프 앤드 돔 코포레이션 |
암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
|
CN114984016A
(zh)
|
2015-03-13 |
2022-09-02 |
雷斯韦洛吉克斯公司 |
用于治疗补体相关疾病之组合物及治疗方法
|
JP6757959B2
(ja)
|
2015-06-16 |
2020-09-23 |
株式会社 PRISM BioLab |
抗がん剤
|
CN107922609B
(zh)
|
2015-07-01 |
2020-04-24 |
加州理工学院 |
基于阳离子粘酸聚合物的递送系统
|
WO2017009751A1
(en)
|
2015-07-15 |
2017-01-19 |
Pfizer Inc. |
Pyrimidine derivatives
|
KR20180058741A
(ko)
|
2015-09-14 |
2018-06-01 |
인피니티 파마슈티칼스, 인코포레이티드 |
이소퀴놀리논의 고체형, 그의 제조 방법, 이를 포함하는 조성물 및 이를 사용하는 방법
|
WO2017103931A1
(en)
*
|
2015-12-17 |
2017-06-22 |
Biokine Therapeutics Ltd. |
Small molecules against cancer
|
WO2017103932A1
(en)
|
2015-12-17 |
2017-06-22 |
Biokine Therapeutics Ltd. |
Small molecules for inhibiting chemokine activity, a kinase activity and/or cancer cells growth
|
WO2017161116A1
(en)
|
2016-03-17 |
2017-09-21 |
Infinity Pharmaceuticals, Inc. |
Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
|
US10919914B2
(en)
|
2016-06-08 |
2021-02-16 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
CA3028718A1
(en)
|
2016-06-24 |
2017-12-28 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
DK3484528T3
(da)
|
2016-07-18 |
2021-02-15 |
Janssen Pharmaceutica Nv |
Tau-pet-billeddannelsesligander
|
JOP20190154B1
(ar)
|
2016-12-22 |
2022-09-15 |
Amgen Inc |
بنز أيزو ثيازول، أيزو ثيازولو [3، 4-b] بيريدين، كينازولين، فثالازين، بيريدو [2، 3-d] بيريدازين ومشتقات بيريدو [2، 3-d] بيريميدين على هيئة مثبطات kras g12c لمعالجة سرطان الرئة، أو سرطان البنكرياس أو سرطان القولون والمستقيم
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
EP4141005B1
(en)
|
2017-09-08 |
2024-04-03 |
Amgen Inc. |
Inhibitors of kras g12c and methods of using the same
|
WO2019213526A1
(en)
|
2018-05-04 |
2019-11-07 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
MX2020010836A
(es)
|
2018-05-04 |
2021-01-08 |
Amgen Inc |
Inhibidores de kras g12c y métodos para su uso.
|
MA52564A
(fr)
|
2018-05-10 |
2021-03-17 |
Amgen Inc |
Inhibiteurs de kras g12c pour le traitement du cancer
|
MA52765A
(fr)
|
2018-06-01 |
2021-04-14 |
Amgen Inc |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
MA52780A
(fr)
|
2018-06-11 |
2021-04-14 |
Amgen Inc |
Inhibiteurs de kras g12c pour le traitement du cancer
|
MA51848A
(fr)
|
2018-06-12 |
2021-04-21 |
Amgen Inc |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
WO2019241327A1
(en)
|
2018-06-13 |
2019-12-19 |
California Institute Of Technology |
Nanoparticles for crossing the blood brain barrier and methods of treatment using the same
|
US20210393632A1
(en)
|
2018-10-04 |
2021-12-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Egfr inhibitors for treating keratodermas
|
CA3117221A1
(en)
|
2018-11-16 |
2020-05-22 |
Amgen Inc. |
Improved synthesis of key intermediate of kras g12c inhibitor compound
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
|
AU2019384118A1
(en)
|
2018-11-19 |
2021-05-27 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
MA54546A
(fr)
|
2018-12-20 |
2022-03-30 |
Amgen Inc |
Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
|
CN113226473A
(zh)
|
2018-12-20 |
2021-08-06 |
美国安进公司 |
Kif18a抑制剂
|
CA3123044A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
WO2020132651A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Kif18a inhibitors
|
CN109776413A
(zh)
*
|
2019-01-29 |
2019-05-21 |
天津科技大学 |
一种具有降糖活性的异喹啉衍生物和应用
|
KR20210146287A
(ko)
|
2019-03-01 |
2021-12-03 |
레볼루션 메디슨즈, 인크. |
이환식 헤테로아릴 화합물 및 이의 용도
|
CN113727758A
(zh)
|
2019-03-01 |
2021-11-30 |
锐新医药公司 |
双环杂环基化合物及其用途
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
AU2020276793A1
(en)
|
2019-05-15 |
2022-01-20 |
Alonbio Ltd. |
Small molecules for treating cancer, inhibiting chemokine activity and/or inducing cell death
|
CN114144414A
(zh)
|
2019-05-21 |
2022-03-04 |
美国安进公司 |
固态形式
|
CN114401953A
(zh)
|
2019-08-02 |
2022-04-26 |
美国安进公司 |
Kif18a抑制剂
|
AU2020326627A1
(en)
|
2019-08-02 |
2022-03-17 |
Amgen Inc. |
KIF18A inhibitors
|
AU2020324963A1
(en)
|
2019-08-02 |
2022-02-24 |
Amgen Inc. |
KIF18A inhibitors
|
JP2022542392A
(ja)
|
2019-08-02 |
2022-10-03 |
アムジエン・インコーポレーテツド |
Kif18a阻害剤としてのピリジン誘導体
|
WO2021081212A1
(en)
|
2019-10-24 |
2021-04-29 |
Amgen Inc. |
Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer
|
CN115873020A
(zh)
|
2019-11-04 |
2023-03-31 |
锐新医药公司 |
Ras抑制剂
|
TW202132314A
(zh)
|
2019-11-04 |
2021-09-01 |
美商銳新醫藥公司 |
Ras抑制劑
|
BR112022008565A2
(pt)
|
2019-11-04 |
2022-08-09 |
Revolution Medicines Inc |
Composto, composição farmacêutica, conjugado, métodos para tratar câncer e um distúrbio relativo à proteína ras
|
KR20220100903A
(ko)
|
2019-11-08 |
2022-07-18 |
레볼루션 메디슨즈, 인크. |
이환식 헤테로아릴 화합물 및 이의 용도
|
MX2022005708A
(es)
|
2019-11-14 |
2022-06-08 |
Amgen Inc |
Sintesis mejorada del compuesto inhibidor de g12c de kras.
|
AR120456A1
(es)
|
2019-11-14 |
2022-02-16 |
Amgen Inc |
Síntesis mejorada del compuesto inhibidor de g12c de kras
|
CN114980976A
(zh)
|
2019-11-27 |
2022-08-30 |
锐新医药公司 |
共价ras抑制剂及其用途
|
AU2021206217A1
(en)
|
2020-01-07 |
2022-09-01 |
Revolution Medicines, Inc. |
SHP2 inhibitor dosing and methods of treating cancer
|
JP2023530351A
(ja)
|
2020-06-18 |
2023-07-14 |
レヴォリューション・メディスンズ,インコーポレイテッド |
Ras阻害剤への獲得耐性を遅延させる、防止する、及び、治療する方法
|
IL300351A
(en)
|
2020-08-07 |
2023-04-01 |
Athos Therapeutics Inc |
Small molecules for the treatment of autoimmune diseases and cancer
|
IL301062A
(en)
|
2020-09-03 |
2023-05-01 |
Revolution Medicines Inc |
Use of SOS1 inhibitors to treat malignancies with SHP2 mutations
|
AU2021345111A1
(en)
|
2020-09-15 |
2023-04-06 |
Revolution Medicines, Inc. |
Indole derivatives as Ras inhibitors in the treatment of cancer
|
CN112047882A
(zh)
*
|
2020-10-15 |
2020-12-08 |
天津科技大学 |
一种异喹啉和喹啉衍生物用于制备降血脂药物方面中的新应用
|
CN117396472A
(zh)
|
2020-12-22 |
2024-01-12 |
上海齐鲁锐格医药研发有限公司 |
Sos1抑制剂及其用途
|
TW202246232A
(zh)
|
2021-02-19 |
2022-12-01 |
英商蘇多生物科學有限公司 |
Tyk2抑制劑及其用途
|
CA3217393A1
(en)
|
2021-05-05 |
2022-11-10 |
Elena S. Koltun |
Ras inhibitors
|
MX2023013084A
(es)
|
2021-05-05 |
2023-11-17 |
Revolution Medicines Inc |
Inhibidores de ras para el tratamiento del cancer.
|
JP2024516450A
(ja)
|
2021-05-05 |
2024-04-15 |
レボリューション メディシンズ インコーポレイテッド |
共有結合性ras阻害剤及びその使用
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
WO2023114954A1
(en)
|
2021-12-17 |
2023-06-22 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
WO2024081916A1
(en)
|
2022-10-14 |
2024-04-18 |
Black Diamond Therapeutics, Inc. |
Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
|